Willem E. Fibbe is at the Department of Immunohaematology and Blood Transfusion and Ton J. Rabelink is at the Department of Medicine, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, Netherlands.
Checking for direct PDF access through Ovid
Immunomodulatory treatment with mesenchymal stromal cells represents a novel therapeutic modality for immune-mediated kidney injury, including in the settings of renal transplantation and glomerulonephritis. A new study illustrates the complexity of aligning clinical trial design, manufacturing and availability of biomarkers in order to turn this promising concept into a therapeutic reality.Refers to Deng, D. Q., Zhang, P., Guo, Y. & Lim, T. O. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann. Rheum. Dis.http://dx.doi.org/10.1136/annrheumdis-2017–211073 (2017)